NVIV | InVivo Therapeutics Holdings Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3010 - 0.4090
52 Week Range	0.2200 - 2.4000
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,609,868
Average Volume	3,769,288
Shares Outstanding	3,105,450
Market Cap	995,918
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-11-15

Valuation
Profitability
Growth
Health
P/E Ratio	-0.10
Forward P/E Ratio	N/A
EPS	-3.28
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	USA
Website	NVIV

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

NVIV's peers: BRTX

*Chart delayed

Analyzing fundamentals for NVIV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see NVIV Fundamentals page.

Watching at NVIV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NVIV Technicals page.